Cytokine Release Syndrome Management Market Forecast: How Big Will It Be by 2030?
Uncover key drivers, emerging technologies, and competitive movements shaping the cytokine release syndrome management market from 2026–2035 with trusted insights from The Business Research Company
Starting from its 2026 valuation, what market size is the Cytokine Release Syndrome Management Market expected to reach by 2030?
The cytokine release syndrome management market size has demonstrated strong growth in recent years. It is projected to expand from $23.76 billion in 2025 to $25.31 billion in 2026, at a compound annual growth rate (CAGR) of 6.5%. The expansion witnessed in the historic period is attributable to the increasing prevalence of CAR-T therapies, the limited array of CRS treatment options, a reliance on corticosteroids, typical hospital-based management, and the substantial mortality risk.
The cytokine release syndrome management market size is projected to experience substantial growth in the coming years, with its value expected to reach $32.35 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.3%. This anticipated growth during the forecast period is attributed to several factors including the expansion of cell therapies, advancements in immunomodulators, improvements in early detection, the establishment of standardized treatment guidelines, and increasing adoption in oncology. Significant trends for this period encompass the rising use of il-6 inhibitors, the broadened application of crs management within car-t therapy, an intensified focus on early intervention protocols, the expansion of intensive care monitoring, and the development of targeted immunomodulators.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24199&type=smp
What Drivers Are Driving Adoption Within The Cytokine Release Syndrome Management Market?
The expanding application of targeted therapies is projected to drive the cytokine release syndrome management market’s growth in the future. These therapies, whether drugs or treatments, are engineered to precisely impede cancer growth and dissemination by disrupting molecular targets crucial for tumor progression. Their growing adoption stems mainly from their capacity to accurately target cancerous cells, thus minimizing harm to healthy ones, boosting treatment effectiveness, and lessening adverse effects compared to conventional treatments. Managing cytokine release syndrome is vital for optimizing targeted therapies, as it controls severe inflammatory responses, thereby improving the safety and efficacy of treatments like CAR-T cell therapy and immune checkpoint inhibitors. For example, in January 2024, the American Society of Gene and Cell Therapy, a US-based organization dedicated to gene and cell therapy, reported that the fourth quarter of 2023 saw a 10% increase in gene therapies undergoing Phase III clinical trials. This represented the initial quarterly uptick of its kind since the third quarter of 2022. Consequently, the expanding application of targeted therapies is propelling the cytokine release syndrome management market forward.
What Segments Are Included Within The Cytokine Release Syndrome Management Market?
The cytokine release syndrome management market covered in this report is segmented –
1) By Treatment Type: Monoclonal Antibodies, Corticosteroids, Intravenous Immunoglobulin (IVIG), Targeted Therapy, Supportive Care, Other Treatment Types
2) By Indication: Chimeric Antigen Receptor (CAR) T-Cell Therapy, Immune Checkpoint Inhibitors, Hematopoietic Stem Cell Transplantation (HSCT), Autoimmune Diseases, Infections, Other Indications
3) By Route Of Administration: Intravenous (IV), Subcutaneous (SC), Oral, Intramuscular (IM), Intrathecal, Other Routes Of Administration
4) By End Users: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics, Research Institutions, Other End Users
Subsegments:
1) By Monoclonal Antibodies: Tocilizumab, Siltuximab, Infliximab, Rituximab
2) By Corticosteroids: Dexamethasone, Prednisone, Methylprednisolone, Hydrocortisone
3) By Intravenous Immunoglobulin (IVIG): Immunoglobulin G (IgG)-Based Intravenous Immunoglobulin, Immunoglobulin A (IgA)-Based Intravenous Immunoglobulin, Immunoglobulin M (IgM)-Based Intravenous Immunoglobulin, Polyvalent Intravenous Immunoglobulin
4) By Targeted Therapy: Janus Kinase (JAK) Inhibitors, Interleukin-6 (IL-6) Inhibitors, Tumor Necrosis Factor-Alpha (TNF-a) Inhibitors, Bruton’s Tyrosine Kinase (BTK) Inhibitors
5) By Supportive Care: Antipyretic Medications, Analgesic Medications, Intravenous Fluids And Electrolyte Solutions, Oxygen Therapy, Vasopressor Agents
6) By Other Treatment Types: Plasmapheresis (Therapeutic Plasma Exchange), Antihistamine Medications, Leukapheresis, Experimental Therapies, Nutritional Support
Which Market Trends Are Opening Growth Opportunities In The Cytokine Release Syndrome Management Market?
Major companies within the cytokine release syndrome management market are concentrating on conducting clinical trials to develop innovative therapies, such as host-directed small molecule drugs. These treatments are intended to modulate the immune response and reduce the severity of cytokine storms without negatively impacting the body’s ability to fight infections or cancer. A host-directed small molecule drug is a low molecular weight compound designed to target the host’s immune signaling pathways, thereby suppressing excessive cytokine production and helping manage cytokine release syndrome (CRS) by preventing immune system overactivation. For instance, in April 2025, CytoAgents Inc., a US-based biotechnology company, announced the successful completion of the first dose-escalation cohort in its Phase 1b/2a clinical trial of CTO1681, a host-directed small molecule drug created to prevent and treat CRS in patients receiving CAR T-cell therapy. The investigational therapy demonstrated a favorable safety profile, with no dose-limiting toxicities or disruption to CAR T-cell efficacy. The trial, which utilizes a rolling six dose-escalation design, is being conducted to assess the safety, tolerability, and preliminary efficacy of CTO1681, as well as to establish the recommended phase 2 dose.
Who Are The Prominent Global Companies Shaping The Cytokine Release Syndrome Management Market Landscape?
Major companies operating in the cytokine release syndrome management market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Incyte Corporation, Swedish Orphan Biovitrum AB, Biocon Limited, MacroGenics Inc., Legend Biotech Corporation, Bluebird Bio Inc., InflaRx N.V., Humanigen Inc.
Access The Complete Report For Deeper Market Insights:
Which Geographic Areas Are Emerging As Strong Markets For The Cytokine Release Syndrome Management Market?
North America was the largest region in the cytokine release syndrome management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cytokine release syndrome management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Cytokine Release Syndrome Management Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24199&type=smp
Browse Through More Reports Similar to the Global Cytokine Release Syndrome Management Market 2026, By The Business Research Company
Release Agents Market Report 2026
https://www.thebusinessresearchcompany.com/report/release-agents-global-market-report
Sustained Release Excipients Market Report 2026
https://www.thebusinessresearchcompany.com/report/sustained-release-excipients-global-market-report
Leukocyte Adhesion Deficiency Management Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
[KClientError] [REQ_ERR: OPERATION_TIMEDOUT] [KTrafficClient] Something is wrong.
